NCT03277248 - Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) | Biotech Hunter

Enrollment

545

Participants

Timeline

Start Date

August 25, 2017

Primary Completion Date

August 4, 2020

Study Completion Date

November 12, 2020

Conditions

Relapsing Multiple Sclerosis (RMS)

Interventions

BIOLOGICAL

Ublituximab

Administered as an IV infusion.

DRUG

Teriflunomide

Film coated tablets administered orally.

DRUG

Oral Placebo

Administered orally.

DRUG

IV Placebo

Administered as an IV Infusion.

Trial Locations (13)

11772

TG Therapeutics RMS Investigational Trial Site, Patchogue

15212

TG Therapeutics RMS Investigational Trial Site, Pittsburgh

33612

TG Therapeutics RMS Investigational Trial Site, Tampa

40513

TG Therapeutics RMS Investigational Trial Site, Lexington

43221

TG Therapeutics RMS Investigational Trial site, Columbus

58018

TG Therapeutics RMS Investigational Trial site, Phoenix

63017

TG Therapeutics RMS Investigational Trial Site, Chesterfield

78258

TG Therapeutics RMS Investigational Trial site, San Antonio

80045

TG Therapeutics RMS Investigational Trial Site, Aurora

87131

TG Therapeutics RMS Investigational Trial Site, Albuquerque

89106

TG Therapeutics RMS Investigational Trial Site, Las Vegas

98122

TG Therapeutics RMS Investigational Trial site, Seattle

07666

TG Therapeutics RMS Investigational Trial Site, Teaneck

All Listed Sponsors

lead

TG Therapeutics, Inc.

INDUSTRY